231 related articles for article (PubMed ID: 11908562)
1. Longterm anticoagulation is preferable for patients with antiphospholipid antibody syndrome. result of a decision analysis.
Brunner HI; Chan WS; Ginsberg JS; Feldman BM
J Rheumatol; 2002 Mar; 29(3):490-501. PubMed ID: 11908562
[TBL] [Abstract][Full Text] [Related]
2. Management of antiphospholipid syndrome.
Tuthill JI; Khamashta MA
J Autoimmun; 2009 Sep; 33(2):92-8. PubMed ID: 19559568
[TBL] [Abstract][Full Text] [Related]
3. The management of thrombosis in the antiphospholipid-antibody syndrome.
Khamashta MA; Cuadrado MJ; Mujic F; Taub NA; Hunt BJ; Hughes GR
N Engl J Med; 1995 Apr; 332(15):993-7. PubMed ID: 7885428
[TBL] [Abstract][Full Text] [Related]
4. [Warfarin in the treatment of antiphospholipid syndrome].
Reshetniak TM; Kondrat'eva LV; Patrusheva NL; Patrushev LI
Ter Arkh; 2007; 79(5):47-54. PubMed ID: 17672075
[TBL] [Abstract][Full Text] [Related]
5. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
6. Evidence based treatment of the antiphospholipid syndrome II. Optimal anticoagulant therapy for thrombosis.
Crowther MA; Wisloff F
Thromb Res; 2005; 115(1-2):3-8. PubMed ID: 15567446
[TBL] [Abstract][Full Text] [Related]
7. How much warfarin is enough in APS related thrombosis?
Erkan D; Lockshin MD
Thromb Res; 2004; 114(5-6):435-42. PubMed ID: 15507275
[TBL] [Abstract][Full Text] [Related]
8. A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis.
Krnic-Barrie S; O'Connor CR; Looney SW; Pierangeli SS; Harris EN
Arch Intern Med; 1997 Oct; 157(18):2101-8. PubMed ID: 9382667
[TBL] [Abstract][Full Text] [Related]
9. Antiphospholipid antibodies in critical illness.
Dentali F; Crowther M
Crit Care Med; 2010 Feb; 38(2 Suppl):S51-6. PubMed ID: 20083914
[TBL] [Abstract][Full Text] [Related]
10. Intensity and duration of anticoagulation therapy in antiphospholipid syndrome.
Les I; Ruiz-Irastorza G; Khamashta MA
Semin Thromb Hemost; 2012 Jun; 38(4):339-47. PubMed ID: 22467528
[TBL] [Abstract][Full Text] [Related]
11. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study.
Jacobs LG; Billett HH; Freeman K; Dinglas C; Jumaquio L
Am J Geriatr Pharmacother; 2009 Jun; 7(3):159-66. PubMed ID: 19616184
[TBL] [Abstract][Full Text] [Related]
12. Current management of antiphospholipid syndrome-related thrombosis.
Puente D; Pombo G; Forastiero R
Expert Rev Cardiovasc Ther; 2009 Dec; 7(12):1551-8. PubMed ID: 19954317
[TBL] [Abstract][Full Text] [Related]
13. Management of antiphospholipid antibody syndrome: a systematic review.
Lim W; Crowther MA; Eikelboom JW
JAMA; 2006 Mar; 295(9):1050-7. PubMed ID: 16507806
[TBL] [Abstract][Full Text] [Related]
14. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS).
Finazzi G; Marchioli R; Brancaccio V; Schinco P; Wisloff F; Musial J; Baudo F; Berrettini M; Testa S; D'Angelo A; Tognoni G; Barbui T
J Thromb Haemost; 2005 May; 3(5):848-53. PubMed ID: 15869575
[TBL] [Abstract][Full Text] [Related]
15. Oral anticoagulation strategies after a first idiopathic venous thromboembolic event.
Aujesky D; Smith KJ; Roberts MS
Am J Med; 2005 Jun; 118(6):625-35. PubMed ID: 15922694
[TBL] [Abstract][Full Text] [Related]
16. Clinical manifestations and outcomes of antithrombotic treatment of the Tan Tock Seng Hospital Singapore antiphospholipid syndrome cohort.
Tan BE; Thong BY; Shivananda S; Han WW; Chng HH
Lupus; 2009 Jul; 18(8):752-8. PubMed ID: 19502274
[TBL] [Abstract][Full Text] [Related]
17. Recurrent venous thrombosis despite 'optimal anticoagulation therapy' for antiphospholipid syndrome--could new oral anticoagulants solve the problem?
Balaban M; Stanrić V; Rincić G; Ledinsky M; Grbac L; Stancić N; Tomasić H
Acta Clin Croat; 2010 Dec; 49(4):469-77. PubMed ID: 21830460
[TBL] [Abstract][Full Text] [Related]
18. Cerebral venous congestion as indication for thrombolytic treatment.
Tsai FY; Kostanian V; Rivera M; Lee KW; Chen CC; Nguyen TH
Cardiovasc Intervent Radiol; 2007; 30(4):675-87. PubMed ID: 17573553
[TBL] [Abstract][Full Text] [Related]
19. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
Flaker GC; Gruber M; Connolly SJ; Goldman S; Chaparro S; Vahanian A; Halinen MO; Horrow J; Halperin JL;
Am Heart J; 2006 Nov; 152(5):967-73. PubMed ID: 17070169
[TBL] [Abstract][Full Text] [Related]
20. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
Sarasin FP; Bounameaux H
Thromb Haemost; 2002 Apr; 87(4):586-92. PubMed ID: 12008939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
